CJC-1295 (no DAC)

A short-acting GHRH analog studied for amplifying the body's own growth-hormone pulses while preserving their natural rhythm.

CJC-1295 without DAC (also called Modified GRF 1-29) is a growth-hormone-releasing-hormone analog: the active 29-amino-acid fragment of natural GHRH with four substitutions that protect it from rapid enzymatic breakdown. The no-DAC form is deliberately short-acting—it amplifies the body's natural GH pulses rather than flattening them into a continuous elevation—which is why it is the form favored in pulsatility-focused research and the GHRH half of the classic Ipamorelin/CJC pairing.

GHRH AnalogPulse AmplifierRecoveryBody Composition

Why BLP features CJC-1295 (no DAC)

Included because it works through the same well-characterized GHRH receptor as Sermorelin and Tesamorelin, with stability modifications that keep release pulsatile, and because it is one of the most widely used GH-axis research peptides—alone and as the GHRH half of the Ipamorelin/CJC blend.

Mechanism

Binds the pituitary receptor for growth-hormone-releasing hormone and stimulates the body's own GH release—the same receptor engaged by Sermorelin and Tesamorelin.

Four amino-acid substitutions protect it from the DPP-IV enzyme that degrades natural GHRH within minutes. Its half-life is roughly 30 minutes and the GH pulse it produces lasts about 1–2 hours.

The “no DAC” distinction matters: the DAC (Drug Affinity Complex) version binds albumin and elevates GH for days, flattening the natural rhythm. The no-DAC form preserves pulsatility, which research associates with a more physiological release pattern.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

Human trial data come mainly from the long-acting DAC form, which produced sustained GH and IGF-1 elevations in controlled studies; the no-DAC form's human pharmacology is inferred from that program plus the extensive clinical history of GRF(1-29) itself (Sermorelin).
No controlled human trial exists for body-composition or recovery outcomes with the no-DAC form on its own.
Reported research-use observations (not controlled endpoints): improved recovery and sleep quality, and gradual body-composition change, most often studied alongside a GHS-class secretagogue.

Preclinical findings

GHRH-receptor mechanism shared with clinically studied analogs (Sermorelin, Tesamorelin).
Stability substitutions characterized in the original GRF-analog medicinal-chemistry literature.

Regulatory status

Investigational; never advanced to approval in any form. Offered strictly for laboratory and research use and is not FDA-approved.

Related research

Ipamorelin/CJC-1295 Ipamorelin Sermorelin Evidence Framework Research Library